ADV’s technology is centered on advanced lentiviral vector platform capable of regulating gene over-expression and silence, in vitro and in vivo. This platform technology is of particular value for large-scale protein production including toxic and membrane proteins, establish stable cell lines for biologic production, and generating transgenic mice, specifically, for the generation of animal models of various diseases and for a systematic, biologically relevant, in vivo approach toward drug target validation.

Specifically-designed lentivector systems such as for protein or antibody expression, for in vitro and in vivo gene silence, and for transgenic mice generation have been developed to meet specific needs.